Literature DB >> 25114412

Chronic idiopathic non-cirrhotic portal vein thrombosis treated with a mesocaval shunt procedure and anticoagulation.

Hamid Shaaban1, Nihar Shah2, Ibrahim Sidhom1.   

Abstract

Portal vein thrombosis (PVT) was first reported in 1868 by Balfour and Stewart and is a medical condition in which the lumen of the portal vein is completely or partially obstructed due to the presence of a thrombus [1]. Inherited (Factor V Leiden and Prothrombin gene mutation G201210A, Protein C, S and Anti thrombin III deficiency) and acquired thrombophilias (Lupus Anticoagulant, myeloproliferative diseases, malignancy, surgery and trauma) account for majority of the cases of PVT.

Entities:  

Year:  2013        PMID： 25114412      PMCID： PMC4115084          DOI： 10.1007/s12288-013-0237-4

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN： 0971-4502            Impact factor:   0.900


  5 in total

Review 1.  Portal vein thrombosis in adults: pathophysiology, pathogenesis and management.

Authors:  D C Valla; B Condat
Journal:  J Hepatol       Date:  2000-05       Impact factor: 25.083

2.  Clinical features, diagnosis and outcome of acute portal vein thrombosis.

Authors:  C L Sheen; H Lamparelli; A Milne; I Green; J K Ramage
Journal:  QJM       Date:  2000-08

3.  Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies.

Authors:  Mats Ogren; David Bergqvist; Martin Björck; Stefan Acosta; Henry Eriksson; Nils H Sternby
Journal:  World J Gastroenterol       Date:  2006-04-07       Impact factor: 5.742

4.  Case of Enlarged Spleen Complicated with Ascites, Both Depending upon Varicose Dilatation and Thrombosis of the Portal Vein.

Authors:  George W Balfour; T Grainger Stewart
Journal:  Edinb Med J       Date:  1869-01

5.  Portal vein thrombosis; risk factors, clinical presentation and treatment.

Authors:  Kirstine K Sogaard; Lone B Astrup; Hendrik Vilstrup; Henning Gronbaek
Journal:  BMC Gastroenterol       Date:  2007-08-15       Impact factor: 3.067
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.